Outlook Therapeutics submits BLA to FDA for its investigational therapy to treat wet AMD

Name: Outlook Therapeutics submits BLA to FDA for its investigational therapy to treat wet AMD
Uploaded: 2022-03-31T15:24:00Z
Description: Outlook Therapeutics submits BLA to FDA for its investigational therapy to treat wet AMD

Proactive Published 31/03/2022

Share X in f @

Outlook Therapeutics (NASDAQ:OTLK) Inc CEO Russ Trenary tells Proactive it has submitted its Biologics License Application to the FDA for ONS-5010, an investigational therapy for the treatment of wet age-related macular degeneration (wet AMD).

If approved, the treatment will be branded as LYTENAVA (bevacizumab-vikg) and could replace the current practice of using unapproved repackaged IV bevacizumab sourced from compounding pharmacies, products that have known risks of contamination and inconsistent potency and availability.